Top Abstract Purchase Related
Home
>
Node
>
Subnode

Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha

Herzog, C.E.; Holmes, K.A.; Tuschong, L.M.; Ganapathi, R.; Zwelling, L.A.

Cancer Research 58(23): 5298-5300

1998

ISSN/ISBN: 0008-5472
PMID: 9850052
Document Number: 486745
Numerous chemotherapeutic agents act via stabilization of a topoisomerase (topo) II-DNA complex. HL-60/AMSA, a human leukemia cell line, is resistant to intercalator-mediated DNA complex formation and cytotoxicity. HL-60/AMSA contains a mutant form of topo IIalpha that was thought to explain this resistance. However, our present data show that expression of topo IIbeta RNA in HL-60/AMSA is only 10% of that in HL-60, and topo IIbeta protein levels are undetectable. Southern analysis of topo IIbeta shows no differences in gene dosage between the two cell lines but does show differences in the restriction patterns. These data suggest that decreased topo IIbeta expression may contribute to the intercalator resistance of HL-60/AMSA cells.

Document emailed within 1 workday
Secure & encrypted payments

Harker, W.G.; Slade, D.L.; Parr, R.L.; Feldhoff, P.W.; Sullivan, D.M.; Holguin, M.H. 1995: Alterations in the topoisomerase Ii alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase Ii beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line Cancer Research 55(8): 1707-1716
Meliksetian, M.B.; Berezkina, E.V.; Pavlenko, M.A.; Grinchuk, T.M. 1999: Mechanisms of drug resistance of two cell lines of human chronic promyelocytic leukemia K562, resistant to DNA topoisomerase Ii inhibitors adriamycin and etoposide Tsitologiia 41(7): 615-621
Mirski, S.E.; Evans, C.D.; Almquist, K.C.; Slovak, M.L.; Cole, S.P. 1993: Altered topoisomerase Ii alpha in a drug-resistant small cell lung cancer cell line selected in VP-16 Cancer Research 53(20): 4866-4873
Watanuki, A.; Ohwada, S.; Fukusato, T.; Makita, F.; Yamada, T.; Kikuchi, A.; Morishita, Y. 2002: Prognostic significance of DNA topoisomerase IIalpha expression in human hepatocellular carcinoma. Anticancer Research 22(2b): 1113-1119
Tanizawa, A.; Pommier, Y. 1992: Topoisomerase i alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture Cancer Research 52(7): 1848-1854
Akimitsu, N.; Kamura, K.; Toné, S.; Sakaguchi, A.; Kikuchi, A.; Hamamoto, H.; Sekimizu, K. 2003: Induction of apoptosis by depletion of DNA topoisomerase IIalpha in mammalian cells Biochemical and Biophysical Research Communications 307(2): 301-307
Durbecq, V.; Desmed, C.; Paesmans, M.; Cardoso, F.; Di Leo, A.; Mano, M.; Rouas, G.; Leroy, J-Y.; Sotiriou, C.; Piccart, M.; Larsimont, D. 2004: Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer International Journal of Oncology 25(5): 1473-1479
Eng, W.K.; McCabe, F.L.; Tan, K.B.; Mattern, M.R.; Hofmann, G.A.; Woessner, R.D.; Hertzberg, R.P.; Johnson, R.K. 1990: Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase i content Molecular Pharmacology 38(4): 471-480
Whitacre, C.M.; Zborowska, E.; Gordon, N.H.; Mackay, W.; Berger, N.A. 1997: Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process Cancer Research 57(8): 1425-1428
Satterwhite, D.J.; White, R.L.; Matsunami, N.; Neufeld, K.L. 2000: Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein Cancer Research 60(24): 6989-6994
Uggla, B.; Tina, E.; Nahi, H.; Paul, C.; Höglund, M.; Sirsjö, A.; Tidefelt, U. 2007: Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia International Journal of Oncology 31(1): 153-160
Coleman, L.W.; Bronstein, I.B.; Holden, J.A. 2001: Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas Anticancer Research 21(2a): 1167-1172
Rene, B.; Fosse, P.; Khelifa, T.; Jacquemin-Sablon, A.; Bailly, C. 1996: The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity Molecular Pharmacology 49(2): 343-350
Sugimoto, Y.; Tsukahara, S.; Oh-hara, T.; Isoe, T.; Tsuruo, T. 1990: Decreased expression of DNA topoisomerase i in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody Cancer Research 50(21): 6925-6930
Gupta, R.S.; Gupta, R.; Eng, B.; Lock, R.B.; Ross, W.E.; Hertzberg, R.P.; Caranfa, M.J.; Johnson, R.K. 1988: Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase i Cancer Research 48(22): 6404-6410
Yao, S.; Murali, D.; Seetharamulu, P.; Haridas, K.; Petluru, P.N.; Reddy, D.G.; Hausheer, F.H. 1998: Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I Cancer Research 58(17): 3782-3786
Chen, A.Y.; Yu, C.; Bodley, A.; Peng, L.F.; Liu, L.F. 1993: A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures Cancer Research 53(6): 1332-1337
Duraj, J.; Takacsova, X.; Sedlak, J.; Sulikova, M.; Hunakova, L.; Bies, J.; Chorvath, B. 2000: PSC 833 induces apoptosis in drug-sensitive human leukemia cell line and modulates resistance to paclitaxel in its multidrug-resistant variant Anticancer Research 20(6b): 4627-4632
de Tinguy-Moreaud, E.; Pourquier, P.; Montaudon, D.; Robert, J. 1994: Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells Anticancer Research 14(1a): 99-103
Ohshima, Y.; Morita, M.; Hirashima, M.; Mori, K.J.; Akutagawa, H.; Katamura, K.; Mayumi, M.; Mikawa, H. 1993: Characterization of an eosinophilic leukemia cell differentiation factor (ELDF) produced by a human T cell leukemia cell line, HIL-3 Experimental Hematology 21(6): 749-754